Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities

J Infect Dis. 2020 Sep 2;222(Suppl 5):S301-S311. doi: 10.1093/infdis/jiaa130.

Abstract

Background: Persons who inject drugs (PWID) are at a disproportionately high risk of HIV infection. We aimed to determine the highest-valued combination implementation strategies to reduce the burden of HIV among PWID in 6 US cities.

Methods: Using a dynamic HIV transmission model calibrated for Atlanta, Baltimore, Los Angeles, Miami, New York City, and Seattle, we assessed the value of implementing combinations of evidence-based interventions at optimistic (drawn from best available evidence) or ideal (90% coverage) scale-up. We estimated reduction in HIV incidence among PWID, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) for each city (10-year implementation; 20-year horizon; 2018 $ US).

Results: Combinations that maximized health benefits contained between 6 (Atlanta and Seattle) and 12 (Miami) interventions with ICER values ranging from $94 069/QALY in Los Angeles to $146 256/QALY in Miami. These strategies reduced HIV incidence by 8.1% (credible interval [CI], 2.8%-13.2%) in Seattle and 54.4% (CI, 37.6%-73.9%) in Miami. Incidence reduction reached 16.1%-75.5% at ideal scale.

Conclusions: Evidence-based interventions targeted to PWID can deliver considerable value; however, ending the HIV epidemic among PWID will require innovative implementation strategies and supporting programs to reduce social and structural barriers to care.

Keywords: HIV; cost-effectiveness; dynamic HIV transmission mode; injection drug use; interventions; localized HIV microepidemics.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Cities / epidemiology
  • Cost of Illness
  • Cost-Benefit Analysis
  • Drug Users / statistics & numerical data
  • Epidemics / economics
  • Epidemics / prevention & control*
  • Epidemics / statistics & numerical data
  • Female
  • HIV Infections / economics
  • HIV Infections / epidemiology*
  • HIV Infections / prevention & control
  • HIV Infections / transmission
  • HIV Testing / economics
  • Health Care Costs
  • Health Plan Implementation / economics
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Models, Economic
  • Opiate Substitution Treatment / economics
  • Opiate Substitution Treatment / methods
  • Pre-Exposure Prophylaxis / economics
  • Pre-Exposure Prophylaxis / organization & administration
  • Prevalence
  • Preventive Medicine / economics*
  • Preventive Medicine / organization & administration
  • Quality-Adjusted Life Years*
  • Substance Abuse, Intravenous / complications
  • Substance Abuse, Intravenous / economics
  • Substance Abuse, Intravenous / rehabilitation*
  • United States / epidemiology
  • Young Adult